Key result
Declining lipoprotein lipase (LPL) levels were causally associated with an elevated risk of lung adenocarcinoma, and elevated LPL levels were positively associated with improved survival.
Why the study?
Lung adenocarcinoma is a leading cause of death worldwide, necessitating the exploration of more biomarkers and therapeutic targets.
Does lipoprotein lipase (LPL) act as a diagnostic and prognostic marker for lung adenocarcinoma?
Population
LUAD tissues, adjacent normal lung tissues, and lung cancer cells
Comparison
LPL activator vs control in lung cancer cells
Design
Bioinformatics analysis and cellular experimental validation study
Authors
Loading...
Hypothesis-generating for lipoprotein lipase in LUAD; requires prospective validation before clinical translation.
Does lipoprotein lipase (LPL) act as a diagnostic and prognostic marker for lung adenocarcinoma?
LPL is identified as a potential diagnostic and prognostic biomarker for lung adenocarcinoma, with its activation inhibiting cancer cell proliferation and migration.
He et al. (2025) studied Lung adenocarcinoma. Lipoprotein lipase (LPL) levels was evaluated on Risk of lung adenocarcinoma and patient survival outcomes. Declining lipoprotein lipase (LPL) levels were causally associated with an elevated risk of lung adenocarcinoma, and elevated LPL levels were positively associated with improved survival.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: